184 related articles for article (PubMed ID: 36267714)
21. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
[TBL] [Abstract][Full Text] [Related]
23. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
[TBL] [Abstract][Full Text] [Related]
25. High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.
Chae HB; Kim MJ; Seo EG; Choi YH; Lee HS; Han JH; Yoon SM; Park SM; Youn SJ
Korean J Hepatol; 2012 Mar; 18(1):75-83. PubMed ID: 22511906
[TBL] [Abstract][Full Text] [Related]
26. [Tenofovir rescue therapy for chronic hepatitis B patients after suboptimal response to treatment with lamivudine plus adefovir dipivoxil].
Ge Y; Li D; Fan Y; Yang H; Lyu W; Fan H; Zhou B; Liu X; Liu Z
Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):697-700. PubMed ID: 25511401
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.
Kim JH; Ahn SH; Ko SY; Choe WH; Kim KH; Kwon SY
Clin Mol Hepatol; 2016 Jun; 22(2):241-9. PubMed ID: 27304549
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV).
Hann HW; Chae HB; Dunn SR
Hepatol Int; 2008 Jun; 2(2):244-9. PubMed ID: 19669311
[TBL] [Abstract][Full Text] [Related]
30. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827
[TBL] [Abstract][Full Text] [Related]
31. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
32. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
Lai XJ; Lian JS; Chen JY; Zhang YM; Jia HY; Zheng L; Yang YD
Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):113-118. PubMed ID: 29804377
[No Abstract] [Full Text] [Related]
33. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis.
Wang HL; Lu X; Yang X; Xu N
Gastroenterol Res Pract; 2016; 2016():3435965. PubMed ID: 27672391
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis.
Wang H; Lu X; Yang X; Ning Q
Int J Clin Exp Med; 2015; 8(11):20111-22. PubMed ID: 26884924
[TBL] [Abstract][Full Text] [Related]
35. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK
J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047
[TBL] [Abstract][Full Text] [Related]
36. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
39. Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.
Park MS; Kim BK; Kim KS; Kim JK; Kim SU; Park JY; Kim DY; Baartarkhuu O; Han KH; Chon CY; Ahn SH
Clin Mol Hepatol; 2013 Mar; 19(1):29-35. PubMed ID: 23593607
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy.
Wang ML; Chen EQ; Zhang DM; Du LY; Yan LB; Zhou TY; Lei XZ; Lei BJ; Lu JJ; Liao J; Tang H
J Viral Hepat; 2017 Nov; 24 Suppl 1():21-28. PubMed ID: 29082645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]